Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Editorial] Alzheimer’s disease: expedition into the unknown

The topline results from EXPEDITION3, a trial of the amyloid β antibody solanezumab in patients with mild Alzheimer’s disease, announced on Nov 23, 2016, sent shares in Eli Lilly (and other companies working on drugs to reduce amyloid β, such as Biogen and Merck) plummeting. But the dementia research community was more phlegmatic. “Clearly, if all the stars aligned then the trial would have been positive”, said Lon Schneider of the California Alzheimer’s Disease Center. The announcement was disappointing, but perhaps not surprising.